SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is rallying to record highs as reports of U.S. approval for advanced chip sales to major Chinese firms alleviate long-standing trade concerns. The community is actively debating whether this momentum will carry the stock toward higher valuation milestones ahead of next week's earnings or if the rapid price appreciation has created a precarious bubble.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors gear up for a plenary oral presentation at the American Urological Association annual meeting, where the company will share extended Phase 3 trial data for its prostate cancer immunotherapy. The community is actively debating the significance of the upcoming clinical update, focusing on the potential for curative-intent benefits and speculating on whether the trial results could drive a major re-rating or acquisition interest.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors digest news that China has agreed to a long-awaited purchase of 200 aircraft, with community discourse heavily polarized between those viewing it as a major breakthrough for U.S.-China relations and skeptics disappointed that the deal fell short of more aggressive rumors. Shareholders are actively debating whether this news is a legitimate catalyst for a sustained recovery or a 'sell the news' event, while many are demanding more clarity on the deal's specific terms and delivery timelines.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is attracting investor attention due to a significant new position from Pershing Square and a flurry of activity surrounding high-profile Trump administration stock disclosures. While the community is actively debating the timing of a rotation from semiconductor stocks into enterprise SaaS, sentiment remains split between those frustrated by recent price consolidation and those viewing the current valuation as a compelling long-term buying opportunity.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is capturing significant attention as traders debate whether rising industrial demand for AI infrastructure will trigger a breakout, or if the metal will succumb to its history of volatility. Community sentiment remains deeply polarized between those betting on a major supply-driven squeeze and others who view the recent price action as a temporary trap.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing high engagement as investors weigh a strong record revenue print and raised guidance against ongoing operational losses. While some are concerned about the stock's recent volatility and post-earnings price movement, the community remains divided between those viewing the dip as a prime accumulation opportunity and those frustrated by the lack of immediate upward momentum.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders debate whether the current price action signals a healthy cooling period or a structural collapse for the overbought semiconductor sector. The community is sharply divided, with bulls aggressively buying the dip on AI growth narratives, while bears point to extreme technical valuations and the potential for a deeper, long-term retracement.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is seeing intense market activity driven by a strategic $100 million investment from the Winklevoss Capital Fund, alongside better-than-expected quarterly revenue figures and growth in its card services. Investors are actively debating the potential for a short squeeze due to high short interest, while community discussions remain divided between speculative bullishness regarding potential Russell 2000 inclusion and concerns over the company's long-term financial health and legal challenges.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire (RDW) is experiencing a surge in volume and upward momentum as investors speculate on its role as critical infrastructure for the space sector, particularly alongside high-profile developments like the upcoming SpaceX IPO. The community is actively debating the stock's transition from a speculative play into a fundamental 'picks and shovels' infrastructure asset, with many pointing to heavy institutional accumulation and recent defense contract wins as key drivers for this strong price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook

(RTTNews) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets...

Royalty Pharma Q1 Earnings Call Highlights

Royalty Pharma (NASDAQ:RPRX) reported what executives described as a "strong start" to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management's remarks on the company's first-q...

RPRX vs. AMGN: Which Stock Is the Better Value Option?

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +6.56% and +3.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High  - Still a Buy?

Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Here's What Happened...

Charles River Gears Up for Q1 Earnings: What's in the Cards?

CRL heads into Q1 earnings results with declining EPS estimates, mixed segment trends and Manufacturing Solutions strength offsetting softness in RMS and DSA.

PFA Pension Forsikringsaktieselskab Acquires New Holdings in Royalty Pharma PLC $RPRX

PFA Pension Forsikringsaktieselskab purchased a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with...

Pictet Asset Management Holding SA Sells 62,539 Shares of Royalty Pharma PLC $RPRX

Pictet Asset Management Holding SA cut its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 313,510 shares of...

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.28	--	--	N/A
Q1 '26	$1.10	$1.30	17.31%	BEAT
Q4 '25	$1.29	$1.47	14.02%	BEAT
Q3 '25	$0.99	$1.17	18.08%	BEAT
Q2 '25	$1.03	$1.14	10.53%	BEAT

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A